Osprey Therapeutics

Osprey Therapeutics appears to be the successor corporate name or later entity associated with Osprey Pharmaceuticals U.S.A., a private biotechnology company developing protein therapeutics for inflammatory and immune diseases. The company’s core technology is its Leukocyte Population Modulator (LPM) platform, a family of fusion proteins designed to selectively target chemokine-activated leukocytes involved in chronic inflammation. Its best-documented lead program is CCL2-LPM, which entered Phase 1b clinical testing for IgA nephropathy. Publicly available evidence for the current Osprey Therapeutics entity is limited and consists mainly of corporate registration records tied to a Carlsbad, California address associated with Ionis/Akcea, so the company’s present operating scope and pipeline status are not well disclosed. Based on available historical sources, it is best characterized as a small private immunology-focused biotech with legacy clinical-stage assets and uncertain current operating visibility.